The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
智能手机日常任务评估 (ASSET):针对早期 AD 的新 IADL 测试
基本信息
- 批准号:10855814
- 负责人:
- 金额:$ 150万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer’s disease biomarkerAmyloidAmyloid beta-ProteinAppointmentAwardBiological MarkersBostonBusinessesCalendarCaregiver BurdenCellular PhoneCerebrospinal FluidClinicClinicalClinical TrialsCognitiveCollaborationsCommunicationComputersDataData SetDementiaDevelopmentDevicesEarly DiagnosisElderlyEmergency department visitFutureGoalsHealth PersonnelHealth StatusHealthcareHomeHospitalsImpaired cognitionImpairmentIndividualLifeMeasuresMedicalMonitorMulticenter StudiesNeuropsychological TestsOutcome MeasureParticipantPatientsPerformancePhasePhysical therapyPhysiciansPositron-Emission TomographyPrevention trialPrimary Care PhysicianQuestionnairesResearchScheduleSecondary PreventionSiteSourceSymptomsSystemTechnologyTechnology TransferTelephoneTestingTimeUnited States Food and Drug AdministrationVisitVoiceWomanamnestic mild cognitive impairmentcognitive changecognitive performancecognitive testingdaily functioningdesigndigitalexperiencefunctional declinehealth assessmentimprovedinstrumentinstrumental activity of daily livingmild cognitive impairmentnovelpatient portalpaymentperformance sitepre-clinicalprodromal Alzheimer&aposs diseaserecruitremote administrationremote assessmentresponsesmartphone applicationtelephone basedyoung adult
项目摘要
Project Summary
Impairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia
and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in
IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis
has been placed on preclinical AD, which consists of individuals with minimal or no symptoms but biological
marker evidence of AD pathology. As secondary prevention trials in preclinical AD are underway and the Food
and Drug Administration (FDA) is providing new guidance for early-stage AD clinical trial outcome measures, it
is imperative that we develop new ecologically valid instruments to be able to track the emergence of subtle yet
clinically meaningful alterations in IADL. Older individuals are increasingly required to interact via the telephone,
computer, and most recently smartphone, to perform essential IADL, such as refilling prescriptions,
communicating with healthcare providers, and performing financial transactions. Most IADL tests do not use
everyday technology and are insufficiently validated. The goal of this project is to complete the development of,
optimize, and validate a novel performance-based IADL instrument that uses a smartphone to assess
healthcare-related daily activities, the Assessment of Smartphone Everyday Tasks (ASSET).
For Phase 1, during Year 1 of the award, we will first develop 5 alternate versions of ASSET. We will then
recruit 20 cognitively normal young adults (YN), 20 cognitively normal older adults (CN), and 20 amnestic mild
cognitive impairment (MCI) participants at a single site, the Center for Alzheimer Research and Treatment
(CART) at Brigham and Women’s Hospital (BWH). Those 60 participants will undergo cognitive testing and
ASSET in the research clinic. The 60 participants will then undergo short-interval (2 weeks) test-retest
reliability of the 6 versions of ASSET (current version and 5 new alternate versions) remotely/at-home.
For Phase 2, during Years 2 and 3 of the award, CART will serve as a coordinating center for 10 Alzheimer’s
Disease Research Center (ADRC) sites, each of which will recruit 20 CN, 20 older adults with subjective cognitive
decline, and 10 MCI participants for a total of 500 participants. Those participants will undergo the Uniform Data
Set (UDS) neuropsychological testing battery as part of their ADRC annual visits, as well as the smartphone app
tasks, ASSET, and a subjective questionnaire at baseline and 1 year later, and in between remotely at home,
they will also perform ASSET on a monthly basis. Finally, AD pathology biomarker data (amyloid positron
emission tomography or cerebrospinal fluid abeta positive/negative) available from other studies at the ADRC
performance sites will be analyzed in about half of participants.
项目概要
日常生活工具性活动 (IADL) 受损是阿尔茨海默病 (AD) 痴呆的一个标志
与 AD 中的认知变化类似,这是患者和护理人员负担的一个主要来源。
IADL 甚至可以在遗忘性轻度认知障碍 (MCI) 阶段之前就开始,最近,人们更加重视这一点。
已被置于临床前 AD 组中,该组由具有最小症状或无症状但生物学症状的个体组成
AD 病理学的标志性证据正在进行,并且食品临床前 AD 的二级预防试验正在进行中。
美国药物管理局 (FDA) 正在为早期 AD 临床试验结果指标提供新的指导,
我们必须开发新的生态有效的工具,以便能够追踪微妙但尚未出现的现象
老年人越来越需要通过电话进行互动,
计算机和最近的智能手机,用于执行基本的 IADL,例如补充处方、
大多数 IADL 测试不使用与医疗保健提供者沟通和进行财务交易。
日常技术并没有得到充分验证该项目的目标是完成以下项目的开发:
优化并验证一种新颖的基于性能的 IADL 仪器,该仪器使用智能手机来评估
与医疗保健相关的日常活动,智能手机日常任务评估(ASSET)。
对于第一阶段,在奖励的第一年,我们将首先开发 ASSET 的 5 个替代版本。
招募 20 名认知正常的年轻人 (YN)、20 名认知正常的老年人 (CN) 和 20 名遗忘症轻度患者
阿尔茨海默病研究与治疗中心的认知障碍 (MCI) 参与者
(CART) 在布莱根妇女医院 (BWH) 这 60 名参与者将接受认知测试和
然后,60 名参与者将在研究诊所进行资产测试。
远程/在家 6 个版本的 ASSET(当前版本和 5 个新的替代版本)的可靠性。
在第二阶段,即该奖项的第 2 年和第 3 年,CART 将作为 10 名阿尔茨海默病患者的协调中心
疾病研究中心(ADRC)站点,每个站点将招募20名CN、20名具有主观认知能力的老年人
下降,总共 500 名参与者中的 10 名 MCI 参与者将接受统一数据。
将 (UDS) 神经心理学测试电池以及智能手机应用程序设置为 ADRC 年度访问的一部分
基线和一年后的任务、资产和主观问卷,以及在家远程进行的问卷调查,
他们还将每月执行 ASSET 最后,AD 病理生物标志物数据(淀粉样蛋白正电子)。
发射断层扫描或脑脊液 abeta 阳性/阴性)可从 ADRC 的其他研究中获得
性能网站大约有一半会被分析。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Using a digital tool to detect early changes in everyday functioning in older adults: A pilot study of the Assessment of Smartphone Everyday Tasks (ASSET).
使用数字工具检测老年人日常功能的早期变化:智能手机日常任务评估 (ASSET) 的试点研究。
- DOI:
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Dubbelman, Mark A;Hall, Tia C;Levesque, Isabella M;Mimmack, Kayden J;Sikkes, Sietske A M;Fischer, Shira H;Rentz, Dorene M;Sperling, Reisa A;Papp, Kathryn V;Amariglio, Rebecca E;Marshall, Gad A
- 通讯作者:Marshall, Gad A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eric Leven其他文献
Eric Leven的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
基于神经退行性疾病前瞻性队列的新烟碱类杀虫剂暴露对阿尔茨海默病的影响及作用机制研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
基于miRNA介导ceRNA网络调控作用的防治阿尔茨海默病及认知障碍相关疾病药物的发现研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
LMTK1调控核内体转运介导阿尔茨海默病神经元Reserve机制研究
- 批准号:81903703
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
MBP酶切L1CAM介导的线粒体自噬在阿尔茨海默病中的作用和机制
- 批准号:81901296
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
基于自组装多肽纳米探针检测蛋白标志物用于阿尔茨海默病精准诊断的研究
- 批准号:31900984
- 批准年份:2019
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 150万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 150万 - 项目类别:
The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
- 批准号:
10748606 - 财政年份:2024
- 资助金额:
$ 150万 - 项目类别:
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 150万 - 项目类别: